News

What Happened? Shares of telehealth company Hims & Hers Health (NYSE:HIMS) jumped 4.1% in the morning session after the ...
Hims and Hers Health is planning to cash in on Novo Nordisk losing its semaglutide drug exclusivity in Canada. The telehealth ...
Hims & Hers Health reports 111% Q1 2025 revenue growth to $586M, driven by personalized treatments & strong margins. Read why ...
Hims & Hers announced plans to expand its weight loss program to Canada in 2026 in connection with the availability of generic semaglutide anywhere in the world.
The move follows a dramatic breakup in June between Hims & Hers and Danish drug maker Novo Nordisk, which makes the brand name weight loss drug Wegovy. Novo Nordisk accused the Hims & Hers of ...
Hims & Hers Health plans to expand into Canada, timing it with the new availability of the generic weight loss medication on the market for the first time.